Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings

Exicure (XCUR) announced that it will present a poster at the upcoming 2026 Tandem Meetings Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy, ASTCT, and Center for International Blood and Marrow Transplant Research, CIBMTR, taking place February 4-7, 2026, in Salt Lake City, UT. The presentation will serve as an encore of data reported previously, highlighting results from Exicure’s open-label, multicenter Phase 2 trial evaluating burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation. Exicure recently shared positive topline data from the trial, which assessed burixafor’s ability to mobilize hematopoietic progenitor cells by blocking CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche.